Substance / Medication

Para-aminosalicylic acid

Overview

Active Ingredient
aminosalicylic acid
RxNorm CUI
7833

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Comparison between 5-aminosalicylic acid (5-ASA) and para-aminosalicylic acid (4-PAS) as potential protectors against Mn-induced neurotoxicity.
Santos Dinamene, Batoreu M Camila, Aschner Michael et al. · Biol Trace Elem Res · 2013
PMID: 23315311ObservationalFull text (PMC)
Para-aminosalicylic acid plasma concentrations in children in comparison with adults after receiving a granular slow-release preparation.
Liwa A C, Schaaf H S, Rosenkranz B et al. · J Trop Pediatr · 2013
PMID: 23174991Observational
Chelation therapy of manganese intoxication with para-aminosalicylic acid (PAS) in Sprague-Dawley rats.
Zheng Wei, Jiang Yue-Ming, Zhang Yanshu et al. · Neurotoxicology · 2009
PMID: 19150464ObservationalFull text (PMC)
Successful oral desensitization to i.v. para-aminosalicylic acid (PAS) using encapsulated PAS dry substance.
Vesenbeckh S M, Becker J, Huhnt C et al. · Infection · 2012
PMID: 21833615Case Report
[Dystrophic calcinosis cutis after subcutaneous administration of para-aminosalicylic acid for treatment of pulmonary tuberculosis].
Meissner Markus, Varwig Domenica, Beier Christian et al. · J Dtsch Dermatol Ges · 2006
PMID: 16734839Case Report
Para-aminosalicylic acid (PAS) desensitization review in a case of multidrug-resistant pulmonary tuberculosis.
Wilson J W, Kelkar P, Frigas E · Int J Tuberc Lung Dis · 2003
PMID: 12757053Case Report
[Two cases of multi-drug-resistant pulmonary tuberculosis with para-aminosalicylic acid (PAS)-induced hypothyroidism].
Mizutani H, Horiba M, Shindoh J et al. · Kekkaku · 2001
PMID: 11712388Case Report
Effect of Sodium Para-Aminosalicylic Acid on Cuproptosis in PC12 Cells Exposed Manganese, Iron, and Copper.
Huang Hai, Ho Thanh-Tung, Huang Zhi-Xin et al. · Biol Trace Elem Res · 2025
PMID: 40199826Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Para-aminosalicylic acid (substance)
SNOMED CT
255666002
UMLS CUI
C0030125
RxNorm CUI
7833

Clinical Data

This intervention maps to 3 entities in the Ltrl knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.